Table 1.
[en] Overall survival as a function of baseline demographic, clinical, and tumor features in the entire cohort
| Variable | Category | No. (%) of all patients | No. (%) of patients who died during follow-up | Unadjusted hazard ratio | 95% confidence interval | p value |
|---|---|---|---|---|---|---|
| Total | 675 (100) | 301 (44.6) | ||||
| Gender | Female | 156 (23.1) | 71 (45.5) | [em] | ||
| Male | 519 (76.9) | 230 (44.3) | 0.99 | 0.77[en]1.3 0 |
0.9952 | |
| Race* | White | 568 (84.1) | 247 (43.5) | [em] | ||
| Black | 100 (14.8) | 53 (53.0) | 1.51 | 1.12[en]2.0 3 |
0.0068 | |
| Age | ≤65 | 234 (34.7) | 77 (32.9) | [em] | ||
| 66[en]75 | 217 (32.1) | 93 (42.9) | 1.26 | 0.93[en]1.7 0 |
0.1348 | |
| ≥76 | 224 (33.2) | 131 (58.5) | 1.99 | 1.50[en]2.6 3 |
0.0001 | |
| Stage | 0 | 305 (45.2) | 98 (32.1) | [em] | ||
| I | 125 (18.5) | 50 (40.0) | 1.29 | 0.92[en]1.8 1 |
0.1473 | |
| II | 93 (13.8) | 44 (47.3) | 1.95 | 1.36[en]2.7 8 |
0.0003 | |
| III | 75 (11.1) | 45 (60.0) | 2.92 | 2.04[en]4.1 6 |
0.0001 | |
| IV | 77 (11.4) | 64 (83.1) | 5.81 | 4.22[en]8.0 0 |
0.0001 | |
| Comorbidity | 0 | 229 (33.9) | 83 (36.2) | [em] | ||
| 1 | 209 (31.0) | 89 (42.6) | 1.64 | 0.99[en]1.8 0 |
0.0585 | |
| 2 | 153 (22.7) | 77 (50.3) | 1.65 | 1.21[en]2.2 6 |
0.0015 | |
| 3 | 84 (12.4) | 52 (61.9) | 2.57 | 1.82[en]3.6 5 |
0.0001 | |
| Grade** | Low (I, II) | 297 (44.0) | 105 (35.4) | [em] | ||
| High (III, IV) |
327 (48.4) | 175 (53.5) | 1.95 | 1.55[en]2.4 5 |
0.0001 |
*
Seven patients were of other ethnicities and were censored owing to small sample size.
**
Fifty-one patients were not assigned a grade and were censored.